Table 1.
Baseline characteristics of patients and study eyes (mITT population)
| Characteristic | DEX (n = 129) | Sham (n = 130) | p value |
|---|---|---|---|
| Mean age (SD), years | 54.6 (9.8) | 53.0 (12.0) | 0.016 |
| Range | 25–78 | 19–77 | |
| Gender, n (%) | 0.054 | ||
| Male | 69 (53.5) | 54 (41.5) | |
| Female | 60 (46.5) | 76 (58.5) | |
| Race, n (%) | NA | ||
| Asian | 129 (100) | 130 (100) | |
| Diagnosis, n (%) | 0.852 | ||
| BRVO | 63 (48.8) | 65 (50.0) | |
| CRVO | 66 (51.2) | 65 (50.0) | |
| Mean duration of ME in eyes with BRVO (SD), days | 125 (86) | 113 (73) | 0.571 |
| Duration, n (%) | |||
| ≤90 days | 32 (50.8) | 36 (55.4) | |
| >90 days | 31 (49.2) | 29 (44.6) | |
| Mean duration of ME in eyes with CRVO (SD), days | 124 (59) | 130 (67) | 0.742 |
| Duration, n (%) | |||
| ≤90 days | 23 (34.8) | 25 (38.5) | |
| >90 days | 43 (65.2) | 40 (61.5) | |
| Previous ocular procedure for RVO, n (%)a | 15 (11.6) | 12 (9.2) | 0.528 |
| Lens status, n (%) | 0.370 | ||
| Phakic | 126 (97.7) | 129 (99.2) | |
| Pseudophakic | 3 (2.3) | 1 (0.8) | |
| Mean IOP (SD), mm Hg | 14.9 (2.9) | 15.0 (2.7) | 0.770 |
| Mean BCVA (SD), letters | 52.6 (10.8) | 53.1 (10.5) | 0.726 |
| Mean CRT (SD), μm | 683 (242) | 643 (213) | 0.149 |
BCVA best-corrected visual acuity, BRVO branch retinal vein occlusion, CRT central retinal thickness, CRVO central retinal vein occlusion, DEX dexamethasone intravitreal implant, IOP intraocular pressure, ME macular edema, mITT modified intent-to-treat, NA not available, RVO retinal vein occlusion, SD standard deviation
aPrevious ocular procedures for RVO included intravitreal injections of anti-vascular endothelial growth factor, intravitreal or intraocular injections of corticosteroid, and laser